It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
HIV-1 envelope (Env) mimetics are candidate components of prophylactic vaccines and potential therapeutics. Here we use a synthetic V3-glycopeptide (“Man9-V3”) for structural studies of an HIV Env third variable loop (V3)-glycan directed, broadly neutralizing antibody (bnAb) lineage (“DH270”), to visualize the epitope on Env and to study how affinity maturation of the lineage proceeded. Unlike many previous V3 mimetics, Man9-V3 encompasses two key features of the V3 region recognized by V3-glycan bnAbs—the conserved GDIR motif and the N332 glycan. In our structure of an antibody fragment of a lineage member, DH270.6, in complex with the V3 glycopeptide, the conformation of the antibody-bound glycopeptide conforms closely to that of the corresponding segment in an intact HIV-1 Env trimer. An additional structure identifies roles for two critical mutations in the development of breadth. The results suggest a strategy for use of a V3 glycopeptide as a vaccine immunogen.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Laboratory of Molecular Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
2 Department of Medicine, Duke University School of Medicine, Duke University Medical Center, Durham, NC, USA; Duke Human Vaccine Institute, Durham, NC, USA
3 Duke Human Vaccine Institute, Durham, NC, USA; Department of Immunology, Duke University School of Medicine, Duke University Medical Center, Durham, NC, USA
4 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
5 Department of Bioorganic Chemistry, Sloan Kettering Institute, New York, NY, USA
6 Department of Biology, Swarthmore College, Swarthmore, PA, USA
7 Department of Chemistry and Biochemistry, Swarthmore College, Swarthmore, PA, USA
8 Laboratory of Molecular Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA; Howard Hughes Medical Institute, Harvard Medical School, Boston, MA, USA